Mineralys Therapeutics CEO Jon Congleton sells $166,082 in inventory

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a $454 million market cap biotech firm, not too long ago reported that its Chief Govt Officer, Jon Congleton, bought 18,333 shares of widespread inventory. The transactions occurred on January 13, 2025, at a weighted common worth of $9.0592 per share, totaling roughly $166,082. The gross sales have been performed underneath a Rule 10b5-1 buying and selling plan, which Congleton adopted on January 30, 2024. In keeping with InvestingPro information, the inventory has declined about 12% over the previous week.

Following these transactions, Congleton retains possession of 877,608 shares of Mineralys Therapeutics. The shares have been bought in a number of transactions, with costs starting from $8.65 to $9.37. Congleton has dedicated to offering detailed data on the precise costs of every transaction upon request. InvestingPro evaluation reveals the corporate maintains a robust liquidity place with a present ratio of 8.55, whereas analyst worth targets vary from $26 to $45. For deeper insights into MLYS’s monetary well being and detailed evaluation, subscribers can entry the great Professional Analysis Report, out there solely on InvestingPro.

In different latest information, Mineralys Therapeutics has acquired FDA approval for a Section 2 scientific trial of lorundrostat, a possible therapy for moderate-to-severe obstructive sleep apnea and hypertension. The trial is about to begin in 2025. In monetary information, Mineralys Therapeutics reported a rise in money and investments to $263.6 million and a web lack of $56.3 million for the third quarter of 2024, primarily because of rising R&D bills. Regardless of the loss, the corporate’s sturdy money place is predicted to help its operations and scientific trials till 2026. The Advance-HTN and Launch-HTN trials for lorundrostat have accomplished enrollment, with outcomes anticipated in 2025. Analysts from InvestingPro preserve a robust purchase consensus on the inventory, with worth targets starting from $26 to $45. These are among the many latest developments at Mineralys Therapeutics.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.